Literature DB >> 23948957

Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer.

Caroline Eymerit-Morin1, Merzouka Zidane, Souhil Lebdai, Stéphane Triau, Abdel Rahmene Azzouzi, Marie-Christine Rousselet.   

Abstract

Low-risk prostate adenocarcinoma is classically managed either with active surveillance or radical therapy (such as external radiotherapy or radical prostatectomy), but both have significant side effects. Vascular-targeted photodynamic therapy (VTP) is a focal therapy proposed as an alternative approach for localized, low-volume, and low-Gleason score (≤6) carcinomas. We report histological modifications observed in prostate biopsies of 56 patients, performed 6 months after VTP using the photosensitizer TOOKAD® Soluble (WST11) and low-energy laser administered in the tumor area transperineally by optic fibers. In 53 patients, we observed sharply demarcated hyaline fibrotic scars, with or without rare atrophic glands, sometimes reduced to corpora amylacea surrounded by giant multinuclear macrophages. Mild chronic inflammation, hemosiderin, and coagulative necrosis were also observed. When residual cancer was present in a treated lobe (17 patients), it was always located outside the scar, most often close to the prostate capsule, and it showed no therapy-related modification. Histopathological interpretation of post-WST11 VTP prostate biopsies was straightforward, in contrast with that of prostate biopsies after radio or hormonal therapy, which introduces lesions difficult to interpret. VTP resulted in complete ablation of cancer in the targeted area.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23948957     DOI: 10.1007/s00428-013-1454-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  17 in total

Review 1.  Photodynamic therapy for focal ablation of the prostate.

Authors:  Nimalan Arumainayagam; C M Moore; Hashim U Ahmed; M Emberton
Journal:  World J Urol       Date:  2010-05-09       Impact factor: 4.226

2.  The effect of Tookad-mediated photodynamic ablation of the prostate gland on adjacent tissues--in vivo study in a canine model.

Authors:  Zheng Huang; Qun Chen; Kenneth C Dole; Al B Barqawi; Yang K Chen; Dominique Blanc; Brian C Wilson; Fred W Hetzel
Journal:  Photochem Photobiol Sci       Date:  2007-08-22       Impact factor: 3.982

3.  Photodynamic therapy of localised prostatic cancer.

Authors:  T Windahl; S O Andersson; L Lofgren
Journal:  Lancet       Date:  1990-11-03       Impact factor: 79.321

Review 4.  Treatment effects in the prostate including those associated with traditional and emerging therapies.

Authors:  Andrew J Evans; Paul Ryan; Theodorus Van derKwast
Journal:  Adv Anat Pathol       Date:  2011-07       Impact factor: 3.875

5.  Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostate.

Authors:  Simone Chevalier; Maurice Anidjar; Eleonora Scarlata; Lucie Hamel; Avigdor Scherz; Hervé Ficheux; Nicolas Borenstein; Laurence Fiette; Mostafa Elhilali
Journal:  J Urol       Date:  2011-05-20       Impact factor: 7.450

6.  Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway.

Authors:  Tiancheng Liu; Lisa Y Wu; Joseph K Choi; Clifford E Berkman
Journal:  Int J Oncol       Date:  2010-04       Impact factor: 5.650

7.  New treatments for localized prostate cancer.

Authors:  Michael Marberger; Peter R Carroll; Michael J Zelefsky; Jonathan A Coleman; Hedvig Hricak; Peter T Scardino; Lucien L Abenhaim
Journal:  Urology       Date:  2008-12       Impact factor: 2.649

8.  Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.

Authors:  John Trachtenberg; Robert A Weersink; Sean R H Davidson; Masoom A Haider; Arjen Bogaards; Mark R Gertner; Andrew Evans; Avigdor Scherz; Joanne Savard; Joseph L Chin; Brian C Wilson; Mostafa Elhilali
Journal:  BJU Int       Date:  2008-05-20       Impact factor: 5.588

Review 9.  Pathology of prostate cancer and focal therapy ('male lumpectomy').

Authors:  Roberta Mazzucchelli; Marina Scarpelli; Liang Cheng; Antonio Lopez-Beltran; Andrea B Galosi; Ziya Kirkali; Rodolfo Montironi
Journal:  Anticancer Res       Date:  2009-12       Impact factor: 2.480

Review 10.  Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.

Authors:  Scott E Eggener; Peter T Scardino; Peter R Carroll; Michael J Zelefsky; Oliver Sartor; Hedvig Hricak; Thomas M Wheeler; Samson W Fine; John Trachtenberg; Mark A Rubin; Mak Ohori; Kentaro Kuroiwa; Michel Rossignol; Lucien Abenhaim
Journal:  J Urol       Date:  2007-10-15       Impact factor: 7.450

View more
  17 in total

1.  Nonthermal Ablation by Using Intravascular Oxygen Radical Generation with WST11: Dynamic Tissue Effects and Implications for Focal Therapy.

Authors:  Simon Y Kimm; Tatum V Tarin; Sébastien Monette; Govindarajan Srimathveeravalli; Daniel Gerber; Jeremy C Durack; Stephen B Solomon; Peter T Scardino; Avigdor Scherz; Jonathan Coleman
Journal:  Radiology       Date:  2016-03-17       Impact factor: 11.105

2.  Dynamic contrast enhanced MRI as a predictor of vascular-targeted photodynamic focal ablation therapy outcome in prostate cancer post-failed external beam radiation therapy.

Authors:  Tristan Barrett; Sean R H Davidson; Brian C Wilson; Robert A Weersink; John Trachtenberg; Masoom A Haider
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

Review 3.  Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight.

Authors:  Andrzej M Bugaj
Journal:  World J Methodol       Date:  2016-03-26

Review 4.  Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.

Authors:  M J Connor; M A Gorin; H U Ahmed; R Nigam
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-12       Impact factor: 5.554

5.  Treatment Effects of WST11 Vascular Targeted Photodynamic Therapy for Urothelial Cell Carcinoma in Swine.

Authors:  Katie S Murray; Ashley G Winter; Renato Beluco Corradi; Stephen LaRosa; Sylvia Jebiwott; Alexander Somma; Haruyuki Takaki; Govindarajan Srimathveeravalli; Michelle Lepherd; Sebastien Monette; Kwanghee Kim; Avigdor Scherz; Jonathan A Coleman
Journal:  J Urol       Date:  2016-02-06       Impact factor: 7.450

Review 6.  A promising anticancer drug: a photosensitizer based on the porphyrin skeleton.

Authors:  Qizhi Zhang; Jun He; Wenmei Yu; Yanchun Li; Zhenhua Liu; Binning Zhou; Yunmei Liu
Journal:  RSC Med Chem       Date:  2020-02-25

7.  Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer.

Authors:  Souhil Lebdai; Arnaud Villers; Eric Barret; Cosmina Nedelcu; Pierre Bigot; Abdel-Rahmène Azzouzi
Journal:  World J Urol       Date:  2015-01-23       Impact factor: 4.226

Review 8.  An update on focal therapy for prostate cancer.

Authors:  Marlon Perera; Nishanth Krishnananthan; Uri Lindner; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2016-09-27       Impact factor: 14.432

9.  Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.

Authors:  Abdel-Rahmene Azzouzi; Souhil Lebdai; Fawzi Benzaghou; Christian Stief
Journal:  World J Urol       Date:  2015-03-19       Impact factor: 4.226

Review 10.  Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project.

Authors:  A W Postema; T M De Reijke; O Ukimura; W Van den Bos; A R Azzouzi; E Barret; D Baumunk; A Blana; A Bossi; M Brausi; J A Coleman; S Crouzet; J Dominguez-Escrig; S Eggener; R Ganzer; S Ghai; I S Gill; R T Gupta; T O Henkel; M Hohenfellner; J S Jones; F Kahmann; C Kastner; K U Köhrmann; G Kovacs; R Miano; R J van Moorselaar; N Mottet; L Osorio; B R Pieters; T J Polascik; A R Rastinehad; G Salomon; R Sanchez-Salas; M Schostak; L Sentker; K J Tay; I M Varkarakis; A Villers; J Walz; J J De la Rosette
Journal:  World J Urol       Date:  2016-02-18       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.